Jpmorgan Chase & CO Replimune Group, Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Replimune Group, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 220,587 shares of REPL stock, worth $1.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

220,587

Previous 486,609 54.67%

Holding current value

$1.01 Million

Previous $5.89 Million 63.51%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$9.75 - $14.31 $2.59 Million - $3.81 Million	-266,022 Reduced 54.67%	220,587 $2.15 Million
Q4 2024 Feb 12, 2025	BUY	$10.54 - $14.93 $2.5 Million - $3.54 Million	237,260 Added 95.15%	486,609 $5.89 Million
Q3 2024 Dec 26, 2024	BUY	$8.09 - $11.23 $65,318 - $90,671	8,074 Added 3.35%	249,349 $2.73 Million
Q3 2024 Nov 08, 2024	BUY	$8.09 - $11.23 $65,318 - $90,671	8,074 Added 3.35%	249,349 $2.73 Million
Q2 2024 Dec 26, 2024	SELL	$5.01 - $9.46 $40,450 - $76,380	-8,074 Reduced 3.24%	241,275 $2.17 Million
Q2 2024 Aug 12, 2024	SELL	$5.01 - $9.46 $154,598 - $291,916	-30,858 Reduced 11.34%	241,275 $2.17 Million
Q1 2024 Dec 26, 2024	BUY	$6.87 - $9.31 $156,526 - $212,119	22,784 Added 9.14%	272,133 $2.22 Million
Q1 2024 May 10, 2024	SELL	$6.87 - $9.31 $225,954 - $306,205	-32,890 Reduced 10.78%	272,133 $2.22 Million
Q4 2023 Dec 26, 2024	BUY	$6.75 - $16.18 $375,799 - $900,805	55,674 Added 22.33%	305,023 $2.57 Million
Q4 2023 Feb 12, 2024	SELL	$6.75 - $16.18 $523,206 - $1.25 Million	-77,512 Reduced 20.26%	305,023 $2.57 Million
Q3 2023 Nov 14, 2023	BUY	$15.96 - $22.18 $1.27 Million - $1.77 Million	79,616 Added 26.28%	382,535 $6.55 Million
Q2 2023 Aug 11, 2023	BUY	$15.65 - $24.1 $2.19 Million - $3.37 Million	139,709 Added 85.6%	302,919 $7.03 Million
Q1 2023 May 18, 2023	BUY	$17.48 - $29.09 $940,214 - $1.56 Million	53,788 Added 49.16%	163,210 $2.88 Million
Q1 2023 May 11, 2023	SELL	$17.48 - $29.09 $756,359 - $1.26 Million	-43,270 Reduced 28.34%	109,422 $1.93 Million
Q4 2022 Feb 13, 2023	SELL	$17.09 - $27.91 $208,139 - $339,915	-12,179 Reduced 7.39%	152,692 $4.15 Million
Q3 2022 Nov 14, 2022	BUY	$15.6 - $21.15 $2.11 Million - $2.86 Million	135,173 Added 455.16%	164,871 $2.85 Million
Q2 2022 Aug 11, 2022	BUY	$13.32 - $19.98 $129,736 - $194,605	9,740 Added 48.8%	29,698 $519,000
Q1 2022 May 11, 2022	SELL	$15.24 - $29.75 $5.51 Million - $10.8 Million	-361,718 Reduced 94.77%	19,958 $339,000
Q4 2021 Feb 10, 2022	SELL	$25.43 - $34.25 $667,664 - $899,233	-26,255 Reduced 6.44%	381,676 $10.3 Million
Q3 2021 Nov 12, 2021	BUY	$28.98 - $39.54 $11.8 Million - $16.1 Million	407,931 New	407,931 $12.1 Million

Others Institutions Holding REPL

# of Institutions

196

Shares Held

77.7M

Call Options Held

2.06M

Put Options Held

2.86M

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $225M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Replimune Group, Inc. Transaction History